Professor Dame Sue Hill Professor Sue Hill DBE FMedSci FRSB FRCP(Hon) FRCPath (Hon) FHCS is the Chief Scientific Officer for England and the head of profession for the healthcare science workforce in the NHS and associated bodies, providing professional leadership and expert clinical advice across the health and care system.  She is a respiratory scientist by background with an international academic and clinical research reputation.

Professor Hill has a broad portfolio of policy responsibilities and has led a variety of major system and workforce transformation initiatives for the Government to improve patient outcomes and service effectiveness in the NHS and beyond.

Sue is the Senior Responsible Officer for Genomics in NHS England, driving the programme to introduce a nationwide Genomic Medicine Service transforming care pathways across a wide range of clinical conditions. This builds on her work in leading the NHS contribution to the 100,000 Genomes Project.  She also provides strategic leadership for the Health Education England Genomics Education Programme.

Sue was made a Dame Commander of the British Empire in the 2018 Queen’s Birthday Honours in recognition of the scale of her contribution to British genomics.

Dr. Richard P. Lifton is the 11^th President of The Rockefeller University, where he is also Carson Family Professor and Head of the Laboratory of Human Genetics and Genomics.  He has pioneered the use of genetics and genomics to understand fundamental mechanisms underlying human diseases.  He is well-known for his discovery that mutations with large effect on human blood pressure act by altering renal salt reabsorption, discoveries that have informed public health efforts and therapeutic strategies used worldwide to prevent heart attacks and strokes, and for his development of exome sequencing for clinical diagnosis and disease gene discovery, which has resulted in dramatic advances linking gene mutations to human disease, identifying new therapeutic  targets for numerous diseases. Lifton graduated summa cum laude from Dartmouth College, obtained M.D. and Ph.D. degrees from Stanford University and completed training in Internal Medicine at Brigham and Women’s Hospital and Harvard Medical School. Prior to Rockefeller, he was on the faculty at Yale School of Medicine for 23 years, where he was Sterling Professor and chair of the Department of Genetics and founder of the Yale Center for Genome Analysis.  He is a member of the National Academy of Sciences, the National Academy of Medicine, and the American Academy of Arts and Sciences. He has served on the governing councils of the former two organizations. He currently serves on the Scientific Advisory Boards of the Simons Foundation for Autism Research, the Chan-Zuckerberg Initiative Biohub, and the JPB Foundation. He is a Director of Roche and its subsidiary Genentech. He has previously served on the Advisory Council to the NIH Director, the Scientific Advisory Boards of the Whitehead Institute and the Broad Institute and the Massachusetts General Hospital. He has served as co-chair of the International Commission on the Clinical Use of Germline Genome Editing, chair of the National Academy of Sciences, National Academy of Engineering and Institute of Medicine Joint Governance Committee for the Reorganization of the National Academies, and as co-chair of the White House/National Institutes of Health Precision Medicine Working Group, which developed the scientific plan for the million person All of Us initiative. He has received numerous awards for his research, including the 2014 Breakthrough Prize in Life Sciences, the 2008 Wiley Prize, and the highest scientific awards of the American Heart Association, the American Society of Nephrology, the Council for High Blood Pressure Research, the International Society for Nephrology and the International Society for Hypertension. He has received honorary doctorates from Northwestern University, Mount Sinai School of Medicine and Yale University.

Mark McCarthy is currently Senior Director of Human Genetics at Genentech, where he leads efforts within the company to use human genetics to advance the understanding of disease and further the development of novel therapeutic and preventative approaches. Prior to his move to the Bay Area in 2019, Mark was Robert Turner Professor of Diabetes Medicine at the University of Oxford. His academic research focuses on the identification and characterisation of genetic variants influencing risk of type 2 diabetes and related traits, and on using those discoveries to drive biological inference and translational opportunities. He played a leading role in major international efforts to identify the genetic variants that influence predisposition to type 2 diabetes including DIAGRAM, T2DGENES and GoT2D: these consortia used genome wide association and sequencing approaches to identify over 400 genetic signals for type 2 diabetes. With collaborators, his research has become increasingly focused on combining genetic and genomic data (gathered from diabetes-relevant tissues such as pancreatic islets) to gain insights into the molecular and pathophysiological mechanisms through which these signals operate. These discoveries reveal new translational opportunities in terms of target validation, risk stratification and biomarker discovery. At both Oxford and Genentech, one major research focus is the capacity to combine genetic and genomic evidence to stratify disease risk, and to dissect the etiological heterogeneity within broad clinical diagnoses (such as type 2 diabetes) in ways that explain individual variation in clinical outcomes such as disease progression, complication risk and therapeutic response.

Wendy Chung, M.D., Ph.D. is a clinical and molecular geneticist and the Kennedy Family Associate Professor of Pediatrics and Medicine.  She received her B.A. in biochemistry and economics from Cornell University, her M.D. from Cornell University Medical College, and her Ph.D. from The Rockefeller University in genetics.  Dr. Chung directs NIH funded research programs in human genetics of obesity, breast cancer, pulmonary hypertension, and birth defects including congenital diaphragmatic hernia and congenital heart disease.  She leads the Precision Medicine Resource in the Irving Institute At Columbia University.  She has authored over 250 peer reviewed papers and 50 reviews and chapters in medical texts.  She was the recipient of the American Academy of Pediatrics Young Investigator Award, the Medical Achievement Award from Bonei Olam, and a career development award from Doris Duke.  Dr. Chung is renowned for her teaching and mentoring and received Columbia University’s highest teaching award, the Presidential Award for Outstanding Teaching.  She was the original plaintiff in the Supreme Court case that overturned the ability to patent genes and the Institute of Medicine Committee on Genetic Testing.  Dr. Chung enjoys the challenges of genetics as a rapidly changing field of medicine and strives to facilitate the integration of genetic medicine into all areas of health care in a medically, scientifically, and ethically sound, accessible, and cost effective manner.

Robert M. Califf, MD, MACC, is the Head of Clinical Policy and Strategy for Verily and Google Health for Verily and Google Health. Prior to this Dr. Califf was the vice chancellor for health data science for the Duke University School of Medicine; director of Duke Forge, Duke’s center for health data science; and the Donald F. Fortin, MD, Professor of Cardiology. He served as Deputy Commissioner for Medical Products and Tobacco in the U.S. Food and Drug Administration (FDA) from 2015-2016, and as Commissioner of Food and Drugs from 2016-2017. A nationally and internationally recognized leader in cardiovascular medicine, health outcomes research, healthcare quality, and clinical research, Dr. Califf is a graduate of Duke University School of Medicine. Dr. Califf was the founding director of the Duke Clinical Research Institute and is one of the most frequently cited authors in biomedical science.

Dr. Eric Green is the Director of the National Human Genome Research Institute (NHGRI) at the U.S. National Institutes of Health (NIH). He is the third NHGRI Director, having been appointed by NIH Director Dr. Francis Collins in 2009.

Dr. Green has been at the Institute for more than 25 years, during which he has had multiple key leadership roles. He served as the Institute’s Scientific Director for 7 years, Chief of the NHGRI Genome Technology Branch for 13 years, and Founding Director of the NIH Intramural Sequencing Center for 12 years.

For just over two decades, Dr. Green directed an independent research program that included integral start-to-finish roles in the Human Genome Project and groundbreaking work on mapping, sequencing, and characterizing mammalian genomes.

Dr. Green earned his M.D. and Ph.D. degrees in 1987 from Washington University in St. Louis; coincidentally, the word “genomics” was coined in that same year. During his career, Dr. Green has authored and co-authored over 375 scientific publications.

Dr. Ginsburg is the founding director for the Center for Applied Genomics & Precision Medicine at the Duke University Medical Center and for MEDx, a partnership between the Schools of Medicine and Engineering to spark and translate innovation.  His research addresses the challenges for translating genomic information into medical practice and the integration of precision medicine into healthcare.

He is a member of the Advisory Council to the Director of NIH and is co-chair of the National Academies Roundtable on Genomic and Precision Health and is co-chair of the Global Genomic Medicine Collaborative.  He has recently served as a member of the Board of External Experts for the NHLBI, the advisory council for the National Center for Accelerating Translational Science, and the World Economics Forum’s Global Agenda Council on the Future of the Health Sector.